Comparison of Molecular Responses between e14a2 and e13a2 BCR-ABL1 Transcripts in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Front-Line Second Generation Tyrosine Kinase Inhibitors: Taiwan CML Study

被引：0
|
作者：
Su, Yi-Jiun
Kuo, Ming-Chung
Teng, Chieh-Lin
Chen, Tsai-Yun
Ma, Ming-Chun
Hsiao, Pei-Ching
Wang, Ming-Chung
Lin, Tung-Huei
Hwang, Wen-Li
Chen, Chih-Cheng
Yang, Youngsen
Pei, Sung-Nan
Huang, Yen-Min
Li, Sin-Syue
Lee, Ming-Yang
Cheng, Hung-I
Shih, Lee-Yung
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1603
引用
收藏
页数：3
相关论文
共 50 条
  • [31] CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSES IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH FIRST-LINE SECOND-GENERATION TYROSINE KINASE INHIBITORS
    Lee, S.
    Choi, S.
    Kim, S.
    Bang, J.
    Oh, Y.
    Park, J.
    Jeon, H.
    Jang, E.
    Kim, D.
    HAEMATOLOGICA, 2013, 98 : 51 - 52
  • [32] Predictive Value of BCR::ABL1 Transcripts Kinetics in the Molecular Relapse of Chronic Myeloid Leukemia Patients after Tyrosine Kinase Inhibitors Discontinuation: Results from the DES-CML Study
    Murbach, Bruna A.
    Oliveira, Gislaine Borba
    Palma, Leonardo Carvalho
    Miranda, Eliana C. M. C. M.
    Amarante, Guilherme D.
    Furlin, Graziele C. P.
    Toni, Isabella Macedo
    De Souza, Carmino
    Figueiredo-Pontes, Lorena
    Pagnano, Katia B.
    BLOOD, 2023, 142
  • [33] Chronic Myeloid Leukemia (CML) Patients With Atypical e1a2 P190 BCR-ABL Translocation Show a Poor Response To Therapy With Tyrosine Kinase Inhibitors (TKI)
    Montoriol-Sabate, Carme
    Martinez-Laperche, Carolina
    Jimenez-Gamiz, P.
    Collado, Rosa
    Minguela-Puras, Alfredo
    Pinan-Frances, M. A.
    Bellosillo, B.
    Martinez-Lopez, Joaquin
    Gonzalez, Marcos
    Larrayoz, Maria Jose
    Calasanz, MaJose
    Gomez-Casares, Maria Teresa
    Gonzalez-Brito, G.
    Soler, Gloria
    Roman, Jose
    Jimenez-Velasco, A.
    Buno, Ismael
    BLOOD, 2013, 122 (21)
  • [34] First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts
    Andrikovics, Hajnalka
    Nahajevszky, Sarolta
    Szilvasi, Aniko
    Bors, Andras
    Adam, Emma
    Kozma, Andras
    Kajtar, Bela
    Barta, Aniko
    Poros, Anna
    Tordai, Attila
    HEMATOLOGICAL ONCOLOGY, 2007, 25 (03) : 143 - 147
  • [35] BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors
    Song, Hye-young
    Noh, Hayeon
    Choi, Soo Young
    Lee, Sung-Eun
    Kim, Soo-Hyun
    Kee, Kyung-Mi
    Yoo, Hea-Lyun
    Lee, Mi-young
    Kang, Ki-Hoon
    Suh, Ji-Hyung
    Yang, Seon-young
    Jang, Eun-Jung
    Lee, Jangik, I
    Kim, Dong-Wook
    CANCER MEDICINE, 2018, 7 (10): : 5107 - 5117
  • [36] Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group
    Iriyama, Noriyoshi
    Fujisawa, Shin
    Yoshida, Chikashi
    Wakita, Hisashi
    Chiba, Shigeru
    Okamoto, Shinichiro
    Kawakami, Kimihiro
    Takezako, Naoki
    Kumagai, Takashi
    Inokuchi, Koiti
    Ohyashiki, Kazuma
    Taguchi, Jun
    Yano, Shingo
    Igarashi, Tadahiko
    Kouzai, Yasuji
    Morita, Satoshi
    Sakamoto, Junichi
    Sakamaki, Hisashi
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (04) : 282 - 287
  • [37] BCR/ABL1 TRANSCRIPT E13A2 IS ASSOCIATED WITH HIGHER CUMULATIVE PROBABILITY OF LOSS OF MAJOR MOLECULAR RESPONSE IN CML PATIENTS TREATED WITH NILOTINIB AS THE 2-ND LINE THERAPY
    Dmytrenko, I.
    Fedorenko, V.
    Martina, Z.
    Sholoyko, V.
    Shlyakhtychenko, T.
    Minchenko, Z.
    Dyagil, I.
    HAEMATOLOGICA, 2017, 102 : 731 - 731
  • [38] BCR-ABL1 Transcript of 7.93% at 3 Months Is an Early Predictor for Long-Term Survival to Second-Line Therapy Using Next Generation Tyrosine Kinase Inhibitors in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia
    Lee, Sung-Eun
    Choi, Soo Young
    Oh, Yun Jeong
    Kim, Soo-Hyun
    Song, Hye-Young
    Yoo, Hea-Lyun
    Lee, Mi-Young
    Chae, Moon-Jung
    Kang, Ki-Hoon
    Hwang, Hee-Jeong
    Jang, Eun-Jung
    Kim, Dong-Wook
    BLOOD, 2014, 124 (21)
  • [39] e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response
    Marce, Silvia
    Mendez, Aleix
    Xicoy, Blanca
    Estrada, Natalia
    Cabezon, Marta
    Sturla, Antonella Luciana
    Garcia, Miriam Ratia
    Angona, Anna
    Amat, Paula
    Escribano Serrat, Silvia
    Scalzulli, Emilia
    Morgades, Mireia
    Senin, Alicia
    Hernandez-Boluda, Juan Carlos
    Ferrer-Marin, Francisca
    Anguita, Eduardo
    Cortes, Montserrat
    Plensa, Esther
    Breccia, Massimo
    Garcia-Gutierrez, Valentin
    Zamora, Lurdes
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (03)
  • [40] Characterization and significance of the Philadelphia negative/BCR-ABL1 positive rearrangement or masked Philadelphia translocation in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single-center study
    Ratajczak, Blazej
    Gniot, Michal
    Przybylowicz-Chalecka, Anna
    Czerwinska-Rybak, Joanna
    Komarnicki, Mieczyslaw
    Lewandowski, Krzysztof
    Jarmuz-Szymczak, Malgorzata
    LEUKEMIA & LYMPHOMA, 2020, 61 (01) : 189 - 193
12345